Osteoporosis:  Nonclinical Evaluation of Drugs Intended for Treatment
2015-769 Osteoporosis Nonclinical Evaluation of Drugs Intended for Treatment
2016-07-28 2016-08-16
FDA-2016-D-1273-0003 FDA-2016-D-1273-0006
04:00:00 04:00:00
https://api.regulations.gov/v4/comments/FDA-2016-D-1273-0003 https://api.regulations.gov/v4/comments/FDA-2016-D-1273-0006
Anonymous Anonymous
Anonymous Anonymous
More information needs to occur on the role of nutrition in bone health. There should be less reliance on drugs and more on role of food that impacts the body. None of the drugs available have a positive impact on body. There are too many negative side effects. Radius Health, Inc. (Radius) is pleased to submit these comments in connection with the Food and Drug Administrations (FDAs) issuance of the draft guidance for industry entitled, Osteoporosis: Nonclinical Evaluation of Drugs Intended for Treatment, released June 14, 2016.  